Raymond James Downgrades Catalyst Biosciences (CBIO) to Market Perform, Following Clinical Business Update, Strategic Business Update
Tweet Send to a Friend
Raymond James analyst Timur Ivannikov downgraded Catalyst Biosciences (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
